Regulating Fixed Dose Combinations: Balancing Therapeutic Utility and Public Health Safety

The Health Ministry's ban on 16 Fixed Dose Combination (FDC) drugs is a critical intervention in India's pharmaceutical regulatory landscape. FDCs involve two or more active ingredients in a single dosage form, traditionally designed to improve patient compliance. However, the Indian market has been flooded with 'irrational' FDCs—combinations that lack scientific justification, offer no additional therapeutic benefit, and often increase the risk of adverse drug reactions. The editorial emphasizes 'evidence-based medicine' as the guiding principle for this ban. This move is significant for two reasons. First, it addresses the escalating crisis of Antimicrobial Resistance (AMR). When antibiotics are included in irrational FDCs, they often result in sub-optimal dosing or unnecessary exposure, allowing bacteria to develop resistance. The 2016 precedent, where 19% of banned FDCs were antibiotic-based, underscores this link. Second, the ban highlights the governance challenge in drug regulation. While the Central Health Ministry sets the policy, enforcement rests with State Drug Controllers. Past lapses, where banned drugs remained on pharmacy shelves, reveal a disconnect in the regulatory chain. For UPSC aspirants, this topic illustrates the role of the Central Drugs Standard Control Organisation (CDSCO) and the legal framework under the Drugs and Cosmetics Act, 1940. It also touches upon the economic aspect of healthcare, as irrational drugs increase out-of-pocket expenditure without improving health outcomes. The policy implication is clear: India must shift from a volume-based pharmaceutical market to one rooted in clinical safety and therapeutic necessity.